Testing a muscle supplement to lower a blood marker in ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This pilot study tests whether a muscle-supporting supplement called HMB can lower a blood marker (IGFBP7) that may be related to ALS. The goal is to see if this supplement is safe and could be a helpful addition to usual care for people with ALS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a diagnosis of ALS (also called Lou Gehrig's disease)
- You can read and write English and give informed consent
- If you are a woman who could become pregnant, you must use birth control (or be post-menopausal or surgically sterile) and have a negative pregnancy test
- You are not currently taking HMB (a common muscle-building supplement) or have not taken it in the last month
- You are not involved in another treatment trial (and have not been in one in the last month), and you do not have high calcium or vitamin D levels
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a transplant of healthy gut bacteria (called a microbiome transplant) can slow down ALS in people whose disease is progressing rapidly. It aims to see if changing the gut environment can help with symptoms and quality of life.
This study tests an investigational drug called NB-4746 for people with ALS. The goal is to see if it can slow the progression of the disease. It is for people diagnosed within the last couple of years who are still able to eat and breathe on their own.
This trial tests a new treatment made from stem cells (called XS228CN) injected into the spine. It is primarily a safety study, but doctors will also watch for any signs the treatment may slow ALS progression.
This study tests a new medicine called BIIB147 to see if it is safe and to learn how it affects people with ALS. It may help slow the progression of the disease.
This trial collects blood and spinal fluid samples from people being checked for ALS. The goal is to find clues (biomarkers) in tiny particles from nerve cells that could help doctors better understand and diagnose ALS.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
Hear when a new Amyotrophic Lateral Sclerosis ALS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.